Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm

Fatty liver disease is an emerging contributor to disease burden worldwide. The past decades of work established the heterogeneous nature of non-alcoholic fatty liver disease (NAFLD) etiology and systemic contributions to the pathogenesis of the disease. This called for the proposal of a redefinitio...

Full description

Bibliographic Details
Main Authors:	Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan
Format:	Article
Language:	English
Published:	MDPI AG 2022-11-01
Series:	International Journal of Molecular Sciences
Subjects:	nonalcoholic fatty liver disease (NAFLD) nonalcoholic steatohepatitis (NASH) metabolic dysregulation-associated fatty liver disease (MAFLD) hepatic fibrosis hepatocellular carcinoma (HCC) cardiovascular disease (CVD)
Online Access:	https://www.mdpi.com/1422-0067/23/23/14762

Similar Items

Utility of human relevant preclinical animal models in navigating NAFLD to MAFLD paradigm
by: Chua, Damien, et al.
Published: (2023)

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
by: Imke Liebold, et al.
Published: (2023-01-01)

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease
by: Umair Iqbal, et al.
Published: (2019-03-01)

Comparative Transcriptomics Analyses in Livers of Mice, Humans, and Humanized Mice Define Human-Specific Gene Networks
by: Chengfei Jiang, et al.
Published: (2020-11-01)

PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS
by: Carla Alessandra SMIDERLE, et al.
Published: (2021-07-01)

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
by: Yusuke Johira, et al.
Published: (2023-06-01)

Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers
by: Tamara Bassal, et al.
Published: (2022-11-01)

Crucial role of T cells in NAFLD-related disease: A review and prospect
by: Tianyu Mao, et al.
Published: (2022-11-01)

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review
by: Jennifer Gallacher, et al.
Published: (2018-06-01)

The role of the microbiome in NAFLD and NASH
by: Aleksandra A Kolodziejczyk, et al.
Published: (2019-02-01)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH
by: Meenakshi Vachher, et al.
Published: (2022-10-01)

MAFLD and CKD: An Updated Narrative Review
by: Alessandro Mantovani, et al.
Published: (2022-06-01)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
by: Leyla Yahaghi, et al.
Published: (2019-12-01)

COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01)

Non-alcoholic fatty liver disease: A review with clinical and pathological correlation
by: Yen-Ying Chen, et al.
Published: (2021-01-01)

Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?
by: Alessandro Mantovani, et al.
Published: (2016-02-01)

Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets
by: Yinshuang Chen, et al.
Published: (2023-06-01)

The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)
by: Amanda Hanson, et al.
Published: (2018-08-01)

Artificial Intelligence in NAFLD: Will Liver Biopsy Still Be Necessary in the Future?
by: Lei Zhang, et al.
Published: (2022-12-01)

Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials
by: Alessandro Mantovani, et al.
Published: (2020-12-01)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl<sub>4</sub>-Induced NASH Mice and the Effect of Obeticholic Acid
by: Nanlin Zhu, et al.
Published: (2021-06-01)

Epidemiology and natural history of NAFLD
by: Della Corte Claudia, et al.
Published: (2015-01-01)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
by: Giovanni Targher
Published: (2020-10-01)

The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
by: Zifeng Yang, et al.
Published: (2023-05-01)

An Update on the Chemokine System in the Development of NAFLD
by: Naoto Nagata, et al.
Published: (2022-06-01)

The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD
by: Brandon J. Perumpail, et al.
Published: (2019-02-01)

Non-alcoholic fatty liver disease – a rapidly growing indication for liver transplantation in the modern world
by: I. M. Iljinsky, et al.
Published: (2019-10-01)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
by: Pallavi Subramanian, et al.
Published: (2022-06-01)

Non-alcoholic fatty liver disease: treatment options based on pathogenic considerations
by: CM Oneta
Published: (2002-09-01)

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
by: Khamis Al Hashmi, et al.
Published: (2024-03-01)

Involvement of the Autophagy-ER Stress Axis in High Fat/Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease
by: Xiu Zhou, et al.
Published: (2020-08-01)

Comparison of MAFLD and NAFLD Characteristics in Children
by: Yunfei Xing, et al.
Published: (2023-03-01)

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
by: Mohammad Habibullah, et al.
Published: (2024-01-01)

Metabolically associated fatty liver disease – a disease of the 21st century: A review
by: Igor V. Maev, et al.
Published: (2022-07-01)

Identification of Accessible Hepatic Gene Signatures for Interindividual Variations in Nutrigenomic Response to Dietary Supplementation of Omega-3 Fatty Acids
by: Yu Shi, et al.
Published: (2021-02-01)

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid
by: V.N. Santos, et al.
Published: (2003-06-01)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
by: Tung-Sung Tseng, et al.
Published: (2023-09-01)

Noninvasive Diagnosis of NAFLD and NASH
by: Valeria Annarita Piazzolla, et al.
Published: (2020-04-01)

Histological findings and NAFLD/NASH Status in liver biopsies of patients subjected to bariatric surgery
by: Marielle Malucelli, et al.
Published: (2023-11-01)

The NAFLD–MAFLD debate through the lens of the Arab world
by: Mina Tharwat, et al.
Published: (2022-01-01)